Month: September 2020

MONTREAL, Sept. 21, 2020 (GLOBE NEWSWIRE) — Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced select preliminary financial results for the third quarter ended August 31, 2020.For the third quarter of fiscal year 2020, the company expects consolidated net revenues to be between $13.8 million and $14.2 million compared to $16.1 million for the third quarter of fiscal year 2019. Revenues for the third quarter of 2020 were primarily impacted by the COVID-19 pandemic, one-time items related to the transition from EGRIFTA® to EGRIFTA SV® as well as higher than expected rebates and chargebacks related to prior reporting periods.“In addition to one-time items impacting our third quarter revenues, COVID-19...

Chicago, IL, Sept. 21, 2020 (GLOBE NEWSWIRE) — FOMO CORP. (US OTC: ETFM)–Under an LOI to merge with FOMO this Fall, Purge Virus LLC (PV) is pleased to announce its Clean Room Initiative (CRI) to help home and business owners at risk from Western U.S. wildfires. For more on the portable devices see: https://purgevirus.com/portable-devices/According to the Lawrence Berkley National Laboratory, “People in the U.S. and many other developed countries are indoors approximately 90% of the time, and may be indoors even more when outdoor air is affected by wildfires When outdoor air particle concentrations increase, indoor air concentrations of particles also increase, particularly in homes because they usually have low efficiency particle filtration systems or no particle filtration.”The recent wildfires have caught the attention of the world,...

– Supplemental New Drug Application Planned for Submission in Q1 2021 –CAMBRIDGE, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the results of the final overall survival (OS) analysis from its global Phase 3 ClarIDHy trial of TIBSOVO® (ivosidenib tablets) in previously treated cholangiocarcinoma patients with an isocitrate dehydrogenase 1 (IDH1) mutation. A consistent trend in improved OS was observed in patients treated with TIBSOVO® compared to those randomized to placebo, but was not statistically significant. The OS endpoint can be affected by crossover, so these results should be taken in the context of the large proportion (70%) of patients in the placebo arm who crossed over to receive...

Vincit OyjLehdistötiedote 21.9.2020 kello 14:00Keusote uudistaa rohkeasti toiminta- ja johtamiskulttuuriaan Vincitin työkalujen avullaSosiaali- ja terveyspalvelujen -toimintaympäristö on valtavan muutospaineen edessä niin rakenteellisten kuin toimintaympäristöön kohdistuvien muutostarpeiden osalta. Matala digitalisaatioaste, monimutkaiset rakenteet ja yksikköjen välisen yhteistyön ja tiedonkulun jäykkyys ovat kuntasektorin keskeisiä haasteita tilanteessa, jossa tarvitaan entistä nopeampia ratkaisuja ongelmiin, jotka ovat entistä kompleksisempia. Näitä haasteita Keski-Uudenmaan sote-kuntayhtymä lähtee edelläkävijänä taklaamaan merkittävällä toiminta- ja johtamiskulttuurin päivityksellä. Muutosta lähdetään tekemään Vincitin kehittämän LaaS-mallin avulla.Johanna Pystynen, Head of Leadership Development, Vincit Oyj: “Työelämän murroksen haasteet...

VANCOUVER, British Columbia, Sept. 21, 2020 (GLOBE NEWSWIRE) — ValOre Metals Corp. (“ValOre”; the “Company”; TSX‐V: VO; OTC: KVLQF; Frankfurt: KEQ0) today announced the addition of a second drill rig to accelerate Phase 1 and Phase 2 of the 2020 core drill program on the Company’s 100%-owned Pedra Branca Platinum Group Element (PGE) Project in northeastern Brazil. ValOre has also augmented the on-site technical team to help execute its newly expanded exploration program. With a CAD $500,000 increase to the existing unsecured revolving credit facility, ValOre is completely funded to finish both Phase 1 and Phase 2 drill programs at Pedra Branca.Pedra Branca Exploration Highlights:Phase 1 drill program has tested six targets with 21 diamond drill holes (“DDH”) to date, totaling 2,210 metres (“m”) of 2,875 m planned. See Table 1 below...

—Live presentation highlighting TRV027 as a potential treatment for COVID-19 acute respiratory distress syndrome (ARDS) / abnormal clottingPosters on OLINVYK benefit-risk profile and TRV250 Phase 1 pharmacokinetics—CHESTERBROOK, Pa., Sept. 21, 2020 (GLOBE NEWSWIRE) — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced three presentations at the virtual 2020 American College of Clinical Pharmacology (ACCP) Annual Meeting, taking place from September 21st to 23rd, 2020.The Company will give a live presentation on TRV027, its AT1 receptor selective agonist being studied as a potential treatment for ARDS / abnormal clotting in COVID-19. Additionally, the Company will present...

DURHAM, N.C. and STAMFORD, Conn., Sept. 21, 2020 (GLOBE NEWSWIRE) — Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, and SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced they have entered into a clinical trial collaboration agreement. Per the agreement, PBCAR269A, Precision BioSciences’ wholly-owned investigational allogeneic chimeric antigen receptor (CAR) T cell therapy candidate targeting B-cell maturation antigen (BCMA), will be evaluated in combination with nirogacestat, SpringWorks’ investigational gamma secretase inhibitor (GSI), in patients...